Interchangeability. An insurmountable fifth hurdle?
Journal Title: Generics and Biosimilars Initiative Journal - Year 2014, Vol 3, Issue 2
Abstract
The arrival of biosimilars has led to considerable debate on how they can be used in clinical practice. A particular concern is related to the question of whether a biosimilar can be safely interchanged with the originator product or other biosimilars. Here we will discuss challenges to the regulatory approach for establishing interchangeability, in the sense of considering biosimilar versions as therapeutic equivalents that could – depending on National or Federal Law – be substituted at the pharmacy level, and compare these to the weight of real-world evidence of the risks of potential differences that could modify longer-term clinical benefit-to-risk. Our discussion will be mainly focused on monoclonal antibodies. We conclude that it will be highly challenging to establish interchangeability of biosimilars, and it should be questioned whether the ‘higher’ standard required for designation of interchangeability adds to the benefit for patients.
Authors and Affiliations
Hans C Ebbers, Paul Chamberlain
Keywords
Related Articles
- EP ID EP354446
- DOI 10.5639/gabij.2014.0302.022
- Views 129
- Downloads 0
Update on clinical practice guideline on the use of epoetin and darbepoetin in adult patients with cancer
Chemotherapy-induced anaemia can be treated using erythropoiesis-stimulating agents (ESAs), but these can cause serious side-effects including tumour progression, venous thromboembolism, and shorter survival. Following e...
Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx
The lack of clear regulatory guidance remains a key bottleneck for securing a second quality-assured source of liposomal amphotericin B (LAmB), the WHO-recommended drug for visceral leishmaniasis. The approval of the fir...
Drug shortages hit US oncologists hard
The number of drug shortages in the US has tripled between 2006 and 2012, with drug shortages now affecting most US oncologists and impacting on patient care. There is a need for new guidelines to control drug substituti...
Statin generics: no differences in efficacy after switching
A study presented at the 2010 Congress of the European Society of Cardiology, had created a considerable stir. Its abstract allegedly showed that the originator drug Lipitor was more beneficial than any of its generic st...
Equal protection under the law: Children and the Best Pharmaceuticals for Children Act
Four changes to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act will markedly improve these programmes: expanded attention paid to neonatal studies, support for the off -patent programme,...